We collect cookies to analyze our website traffic and performance; we never collect any personal data. Cookie Policy
Accept
NEW YORK DAWN™NEW YORK DAWN™NEW YORK DAWN™
Notification Show More
Font ResizerAa
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Reading: Intraarterial radionuclide remedy discovered protected and efficient for superior meningioma sufferers
Share
Font ResizerAa
NEW YORK DAWN™NEW YORK DAWN™
Search
  • Home
  • Trending
  • New York
  • World
  • Politics
  • Business
    • Business
    • Economy
    • Real Estate
  • Crypto & NFTs
  • Tech
  • Lifestyle
    • Lifestyle
    • Food
    • Travel
    • Fashion
    • Art
  • Health
  • Sports
  • Entertainment
Follow US
NEW YORK DAWN™ > Blog > Health > Intraarterial radionuclide remedy discovered protected and efficient for superior meningioma sufferers
Intraarterial radionuclide remedy discovered protected and efficient for superior meningioma sufferers
Health

Intraarterial radionuclide remedy discovered protected and efficient for superior meningioma sufferers

Last updated: December 11, 2024 8:11 pm
Editorial Board Published December 11, 2024
Share
SHARE

Transaxial slices of baseline positron emission tomography (PET) and fused PET/magnetic resonance imaging (MRI; left) reveal a somatostatin receptor-expressing meningioma within the left cavernous sinus (white and black arrows). After 4 cycles of peptide receptor radionuclide remedy (PRRT), a whole remission in response to the Response Evaluation in Neuro-Oncology in addition to PET standards was recorded (proper). Scale bars denote standardized uptake values. Credit score: A Amerein, M Kircher, C Lapa, et al., College of Augsburg, Augsburg, Germany.

Radionuclide remedy delivered on to an artery is protected and possible for sufferers with superior meningioma, in response to new analysis printed within the December challenge of The Journal of Nuclear Drugs. Within the first long-term examine of intraarterial peptide receptor radionuclide remedy (PRRT) in superior meningioma, sufferers noticed improved radiologic and medical illness management in contrast with intravenous PRRT, with no extra toxicity.

Meningiomas are the commonest major neoplasms of the central nervous system and account for greater than one-third of all circumstances. Meningiomas are largely labeled as benign, however 10–15% of circumstances are thought-about atypical or malignant. The popular remedy is surgical procedure with exterior beam radiotherapy. Nevertheless, 30–40% of lesions are ineligible for surgical procedure as a result of their location. Moreover, recurrence charges are notably excessive.

“For meningioma patients who are ineligible for surgery or who experience tumor recurrence, treatment options are limited,” acknowledged Adriana Amerein, MD, nuclear medication resident at College Hospital Augsburg in Augsburg, Germany. “Due to the high expression of somatostatin receptors in most meningiomas, radiopharmaceutical therapy offers a viable therapeutic alternative for patients. Intraarterial administration of the radiopharmaceutical might boost the achievable radiation dose to the tumor.”

Within the examine, researchers assessed the long-term security and efficacy of intraarterial PRRT in sufferers with superior, progressive meningioma. 13 sufferers underwent one to 4 cycles of intraarterial PRRT with 177Lu-HA-DOTATATE. Security and remedy response was evaluated in response to medical standards, and outcomes had been in contrast with intravenous PRRT.

Therapy with intraarterial PRRT was nicely tolerated, with solely transient adversarial results. The median progression-free survival for intraarterial PRRT was 18 months, and the median total survival was not reached after 43 months. Roughly 80% of the sufferers confirmed radiologic illness management after intraarterial PRRT, in comparison with 40% after intravenous PRRT.

“These findings show that intraarterial administration of radiopharmaceutical therapy in meningioma is feasible, safe, and could be a promising therapeutic option in the future,” stated Constantin Lapa, MD, nuclear medication doctor at College Hospital Augsburg. “Looking forward, personalized dosing and combination therapies utilizing intraarterial PRRT could further improve results for patients who don’t respond to conventional therapies.”

Extra info:
Adriana Amerein et al, Intraarterial Administration of Peptide Receptor Radionuclide Remedy in Sufferers with Superior Meningioma: Preliminary Security and Efficacy, Journal of Nuclear Drugs (2024). DOI: 10.2967/jnumed.124.268217

Offered by
Society of Nuclear Drugs and Molecular Imaging

Quotation:
Intraarterial radionuclide remedy discovered protected and efficient for superior meningioma sufferers (2024, December 11)
retrieved 11 December 2024
from https://medicalxpress.com/information/2024-12-intraarterial-radionuclide-therapy-safe-effective.html

This doc is topic to copyright. Aside from any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is supplied for info functions solely.

You Might Also Like

The years 2002 to 2022 noticed a rise in teen handgun-carrying in Florida

1 in 5 chubby adults may very well be reclassified as overweight in line with new framework

Matching your exercises to your persona may make exercising extra satisfying and provide you with higher outcomes

What’s behind the large enhance in early-onset gastrointestinal cancers?

Medical hashish program modifications drastically when including anxiousness as a qualifying situation, examine finds

TAGGED:advancedeffectiveIntraarterialmeningiomapatientsradionuclidesafetherapy
Share This Article
Facebook Twitter Email Print

Follow US

Find US on Social Medias
FacebookLike
TwitterFollow
YoutubeSubscribe
TelegramFollow
Popular News
Russia May Be Seeking Pretext for Ukraine Invasion, Officials Say
World

Russia May Be Seeking Pretext for Ukraine Invasion, Officials Say

Editorial Board February 21, 2022
U.S. grownup weight problems price fell in 2023, as use of GLP-1 meds rose
Heir Apparent or Afterthought? The Frustrations of Kamala Harris.
Metro-North and Amtrak in heavy delays after energy line failure in Connecticut
Patrick Mahomes suffers ankle harm in Chiefs’ win vs. Browns: ‘It’s not damaged’

You Might Also Like

Biobank information helps clarify why some people expertise extra uncomfortable side effects from antidepressants
Health

Biobank information helps clarify why some people expertise extra uncomfortable side effects from antidepressants

July 8, 2025
New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels
Health

New blood biomarker predicts development of Alzheimer’s illness even in its earliest levels

July 8, 2025
Overview compares efficacy, security of therapies for hidradenitis suppurativa
Health

Overview compares efficacy, security of therapies for hidradenitis suppurativa

July 7, 2025
The parable of 200 day by day meals selections: Research challenges widely-cited declare
Health

The parable of 200 day by day meals selections: Research challenges widely-cited declare

July 7, 2025

Categories

  • Health
  • Sports
  • Politics
  • Entertainment
  • Technology
  • World
  • Art

About US

New York Dawn is a proud and integral publication of the Enspirers News Group, embodying the values of journalistic integrity and excellence.
Company
  • About Us
  • Newsroom Policies & Standards
  • Diversity & Inclusion
  • Careers
  • Media & Community Relations
  • Accessibility Statement
Contact Us
  • Contact Us
  • Contact Customer Care
  • Advertise
  • Licensing & Syndication
  • Request a Correction
  • Contact the Newsroom
  • Send a News Tip
  • Report a Vulnerability
Term of Use
  • Digital Products Terms of Sale
  • Terms of Service
  • Privacy Policy
  • Cookie Settings
  • Submissions & Discussion Policy
  • RSS Terms of Service
  • Ad Choices
© 2024 New York Dawn. All Rights Reserved.
Welcome Back!

Sign in to your account

Lost your password?